Serum soluble toll-like receptor 2: a novel biomarker for systemic lupus erythematosus disease activity and lupus-related cardiovascular dysfunction

Aim To assess the serum levels of soluble toll‐like receptor (sTLR2) as an endogenous negative regulator of TLR2 signaling in systemic lupus erythematosus (SLE) patients, to investigate the correlation between sTLR2 and SLE disease activity index (SELDAI), SLE‐related cardiovascular risk factors and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of rheumatic diseases 2016-07, Vol.19 (7), p.685-692
Hauptverfasser:	Houssen, Maha E., El-Mahdy, Rasha H., Shahin, Dina A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenal Cortex Hormones - therapeutic use Adult Antirheumatic Agents - therapeutic use Biomarkers - blood Case-Control Studies Creatinine - blood Cross-Sectional Studies Diastole Down-Regulation Echocardiography, Doppler Enzyme-Linked Immunosorbent Assay Female Humans Hydroxychloroquine - therapeutic use Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - blood Hypercholesterolemia - etiology Lipids - blood Lupus Erythematosus, Systemic - blood Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - diagnosis Lupus Erythematosus, Systemic - drug therapy lupus-related cardiovascular risk factors Male systemic lupus erythematosus TLR2 signaling (sTLR2) Toll-Like Receptor 2 - blood Uric Acid - blood Ventricular Dysfunction, Left - blood Ventricular Dysfunction, Left - diagnostic imaging Ventricular Dysfunction, Left - etiology Ventricular Dysfunction, Left - physiopathology Ventricular Function, Left Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!